DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

Recruiting

Conditions: Graft-versus-Host Disease

Interventions: Other: ruxolitinib

First Posted Date: 2022-11-18

Last Posted Date: 2025-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 127

Registration Number: NCT05621733

Locations: 🇰🇷
Novartis Investigative Site, Taegu, Korea, Republic of

French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Other: T315I
Other: 3L Therapy

First Posted Date: 2022-11-17

Last Posted Date: 2022-11-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT05619978

Locations: 🇫🇷
Novartis Investigative Site, Lyon, France

Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure

Completed

Conditions: Chronic Heart Failure

Interventions: Drug: sacubitril/valsartan

First Posted Date: 2022-11-14

Last Posted Date: 2022-11-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9230

Registration Number: NCT05613140

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation

Completed

Conditions: Chronic Myeloid Leukemia

First Posted Date: 2022-11-09

Last Posted Date: 2023-04-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 164

Registration Number: NCT05611216

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: Nivolumab
Drug: Pembrolizumab
Combination Product: Dabrafenib+Trametinib
Combination Product: Ipilimumab+Nivolumab
Combination Product: Vemurafenib+Cobimetinib
Combination Product: Encorafenib+Binimetinib

First Posted Date: 2022-11-09

Last Posted Date: 2023-04-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1975

Registration Number: NCT05611229

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Siremadlin

First Posted Date: 2022-10-31

Last Posted Date: 2025-05-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT05599932

Locations: 🇺🇸
Texas Liver Institute, San Antonio, Texas, United States
🇺🇸
Clinical Pharmacology of Miami LLC, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy

Phase 2

Recruiting

Conditions: Achilles Tendinopathy

Interventions: Drug: NGI226
Drug: Placebo

First Posted Date: 2022-10-25

Last Posted Date: 2025-04-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT05592990

Locations: 🇺🇸
Tucson Orthopedic Institute, Tucson, Arizona, United States
🇺🇸
Advanced Research LLC, Deerfield Beach, Florida, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

and more 1 locations

Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)

Conditions: Hidradenitis Suppurativa (HS)

First Posted Date: 2022-10-18

Last Posted Date: 2023-10-25

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05583604

Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

Completed

Conditions: Multiple Sclerosis

Interventions: Other: Ofatunumab

First Posted Date: 2022-10-13

Last Posted Date: 2022-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2101

Registration Number: NCT05576779

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China

Completed

Conditions: Retinopathy of Prematurity

Interventions: Other: Ranibizumab

First Posted Date: 2022-10-13

Last Posted Date: 2025-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT05576792

Locations: 🇨🇳
Novartis Investigative Site, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy